Previous Close | 2.4800 |
Open | 2.3600 |
Bid | 2.3700 x 21500 |
Ask | 2.3800 x 800 |
Day's Range | 2.2400 - 2.4500 |
52 Week Range | 1.6700 - 12.0400 |
Volume | |
Avg. Volume | 8,291,139 |
Market Cap | 581.736M |
Beta (5Y Monthly) | 1.80 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.0560 |
Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.84 |
Subscribe to Yahoo Finance Plus to view Fair Value for NVTA
Invitae (NYSE: NVTA), a leading medical genetics company, has announced that aerospace, transportation and industrial supplies veteran William H. Osborne has been appointed to its board of directors and will also serve on its audit committee, effective January 26, 2023.
The popular growth investor publishes her daily transactions. She keeps buying Tesla as well as some low-priced genetics specialists.
Invitae CEO Ken Knight takes the questions and pushes out the answers on the genetic testing company's plans.